enGene Holdings Inc. (NASDAQ:ENGN) Short Interest Up 472.4% in April

enGene Holdings Inc. (NASDAQ:ENGN) saw a large growth in short interest during the month of April. As of April 15th, there was short interest totalling 72,700 shares, a growth of 472.4% from the March 31st total of 12,700 shares. Currently, 1.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 51,000 shares, the days-to-cover ratio is presently 1.4 days.

Insider Buying and Selling

In other enGene news, major shareholder De Solidarite Des Travai Fonds sold 47,854 shares of enGene stock in a transaction that occurred on Monday, April 22nd. The stock was sold at an average price of $15.00, for a total value of $717,810.00. Following the transaction, the insider now directly owns 3,036,153 shares of the company’s stock, valued at approximately $45,542,295. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. Vivo Capital LLC bought a new stake in enGene during the 4th quarter valued at approximately $6,264,000. Omega Fund Management LLC bought a new stake in enGene during the 4th quarter valued at approximately $10,441,000. BVF Inc. IL bought a new stake in enGene during the 4th quarter valued at approximately $20,777,000. Finally, Fcpm Iii Services B.V. bought a new stake in enGene during the 4th quarter valued at approximately $80,097,000. Institutional investors own 64.16% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on ENGN shares. Morgan Stanley started coverage on enGene in a research note on Friday, March 8th. They set an “overweight” rating and a $40.00 target price on the stock. Leerink Partnrs reissued an “outperform” rating on shares of enGene in a research note on Tuesday, February 20th. Wells Fargo & Company assumed coverage on enGene in a research report on Monday, April 22nd. They set an “overweight” rating and a $30.00 price target on the stock. UBS Group assumed coverage on enGene in a research report on Thursday, March 28th. They set a “buy” rating and a $37.00 price target on the stock. Finally, Guggenheim assumed coverage on enGene in a research report on Monday, April 15th. They set a “buy” rating and a $34.00 price target on the stock. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, enGene has an average rating of “Buy” and an average target price of $34.40.

enGene Price Performance

Shares of NASDAQ:ENGN traded up $0.78 during midday trading on Friday, reaching $15.50. 113,417 shares of the company’s stock traded hands, compared to its average volume of 36,859. enGene has a one year low of $6.69 and a one year high of $43.00. The stock’s 50 day moving average price is $16.20.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.